Dr. Pratibha Sareen Binder, MD

Dr. Binder practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Binder's NPI, 1174758031, was assigned on May 21, 2009. Dr. Binder graduated from UC Irvine School of Medicine in 2009. Dr. Binder holds California license A149945.

Dr. Binder's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Binder's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Binder is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health. Dmand AI also links Dr. Binder to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Binder practices, 2 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Binder's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Binder is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology. Dmand AI has Dr. Binder's licenses on file in 2 states: California and Missouri.

Dmand AI lists hysterectomy among the conditions Dr. Binder treats.

CMS data shows 278 Medicare services from Dr. Binder across 5 procedure codes in 2024, for 117 Medicare patients. Medicare paid $28,176 for them.

CMS counts 117 Medicare patients who saw Dr. Binder in 2024. The largest group is 65 to 74, with 55 patients. 72% of them have high blood pressure, and 69% have high cholesterol. 30% are also on Medicaid. Their average risk score is 2.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Binder's median patient age at 61, with 99% women.

In 2024, Dr. Binder wrote 255 Medicare Part D claims for 61 patients. 83% of them were for generic drugs. CMS names the drug for 111 of them, across 6 drugs with 11 or more claims each, at $14,533 in total drug cost. In 2023, CMS named 57 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Binder for performance year 2024, reported as part of a group. Dr. Binder accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Binder as offering telehealth. CMS counts 13 procedures of removal of the uterus by Dr. Binder, more than 87% of the clinicians it reports for that procedure.

Dmand AI links 26 papers to Dr. Binder, published from 2014 to 2024. 2020 was the busiest year, with 7. The most frequent topics are Uterine Cervical Neoplasms, Ovarian Neoplasms and Antineoplastic Agents. Dr. Binder has published most often in Gynecol Oncol. Dr. Binder's most frequent co-authors are Ramez Nassef Eskander, MD, Michael Thomas McHale, MD and Cheryl Christine Saenz, MD.

Dmand AI links Dr. Binder to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Carcinosarcoma and Neoplasms, Complex and Mixed.

CMS Open Payments shows 74 general payments to Dr. Binder from 19 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 84% of the total. Eisai Inc. paid the most, $10,551.

Dr. Binder graduated from UC Irvine School of Medicine in 2009. Dr. Binder is a member of American College of Obstetricians and Gynecologists, American Society of Clinical Oncology, International Gynecologic Cancer Society and Society of Gynecologic Oncology.

Dr. Binder is in network with 15 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.